Clinical Trials Directory

Trials / Completed

CompletedNCT02996227

Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

Comparison of Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine: A Randomized, Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
514 (actual)
Sponsor
The Cleveland Clinic · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Comparison of Bilateral Transversus Abdominis Plane Block with Exparel versus Continuous Epidural Analgesia With Bupivacaine

Detailed description

The investigator goal is to compare the analgesic efficacy of TAP blocks with liposomal bupivacaine (Exparel) and continuous epidural blocks in patients who are scheduled for major lower abdominal surgery. To assess whether TAP block with Exparel is noninferior to continuous epidural analgesia on pain management, defined as noninferior for both pain control and total opioid consumption for 72 hours, in patients who had major lower abdominal surgery.

Conditions

Interventions

TypeNameDescription
PROCEDURETAP blockTransversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
PROCEDUREEpidural analgesiaEpidural catheters will be inserted preoperatively.
DRUGEXPARELOnce the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
DRUGBupivacaineOnce an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.

Timeline

Start date
2016-12-01
Primary completion
2019-06-01
Completion
2019-10-01
First posted
2016-12-19
Last updated
2024-01-31
Results posted
2024-01-31

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02996227. Inclusion in this directory is not an endorsement.